Company Medigen Biotechnology Corp.

Equities

3176

TW0003176004

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Sector Other Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
38.75 ^TWD	0.00%		-0.13%	-13.50%

Mar. 29	The Ministry of Health and Welfare Approves Collaborative Autologous Gamma-Delta T Cell Therapy Project by Medigen Biotechnology Corp. and Chi Mei Hospital	CI
Mar. 26	Taiwan MOHW Approves A New Version of the Collaborative Autologous Natural Killer Cell Therapy Project by Medigen Biotechnology Corp. and Changhua Christian Hospital	CI

MEDIGEN BIOTECHNOLOGY CORP. is a Taiwan-based company principally engaged in the wholesales and distribution of general drugs. The Company is engaged in the licensing of technologies, the provision of technical services and testing services of nucleic acids. The Company's products and services include human leukocyte antigen (HLA) ABDR typing reagents, HLA typing and testing services, HLA SBT high-resolution typing reagents, HLA ABCDRDQ typing kits, nucleic acid testing reagents for the genotyping of human platelet, nucleic acid extraction instruments and reagents and blood screening specialized automated nucleic acid detection platforms. It also provides medical beauty care products. The Company distributes its products in Taiwan market and to overseas markets.

TWD in Million	2022	Weight	2023	Weight	Delta
Generic Drugs, Medical Beauty Products and Health Food 61.2 %	607	57.4 %	709	61.2 %	+16.91%
New Drugs and Vaccine Development 33.7 %	365	34.6 %	390	33.7 %	+6.73%
Nucleic Acid Testing 5.1 %	84	7.9 %	59	5.1 %	-29.53%

TWD in Million	2022	Weight	2023	Weight	Delta
Taiwan 99.0 %	1,005	95.2 %	1,146	99.0 %	+14.03%
China 0.5 %	40	3.7 %	6	0.5 %	-84.10%
Other 0.4 %	11	1.0 %	5	0.4 %	-54.82%

Managers	Title	Age	Since
Stanley Chang CEO	Chief Executive Officer	81	03-06-08
Ya Ling Chiang COO	Chief Operating Officer	-	-
Wei Chi Wu IRC	Investor Relations Contact	-	-
Alarng Chang PRN	Corporate Officer/Principal	-	16-06-30

Members of the board	Title	Age	Since
Tzu Liang Huang BRD	Director/Board Member	-	01-08-12
Stanley Chang CEO	Chief Executive Officer	81	03-06-08
Ming Li Chuang BRD	Director/Board Member	-	01-08-12
Pei Wei Chen BRD	Director/Board Member	-	21-08-01
Po Hsiung Lai BRD	Director/Board Member	-	15-06-21
Hsiu Ming Chuang BRD	Director/Board Member	-	18-06-05

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	139,229,755	104,116,755 ( 74.78 %)	0	74.78 %

Name	Equities	%	Valuation
First Securities Investment Trust Co. Ltd. 0.0323 %	45,000	0.0323 %	54 767 NT$
Hua Nan Securities Investment Trust Co. Ltd. 0.0251 %	35,000	0.0251 %	42 597 NT$
Pension Reserves Investment Management Board 0.008750 %	12,193	0.008750 %	14 839 NT$
DFA Australia Ltd. 0.007970 %	11,106	0.007970 %	13 517 NT$
Yuanta Securities Investment Trust Co., Ltd. 0.000722 %	1,006	0.000722 %	1 224 NT$

Name	Equities	%	Valuation
MEDIGEN VACCINE BIOLOGICS CORPORATION 19.49%	64,058,844	19.49%	104,084,091 $

Medigen Biotechnology Corp.

14th Floor, Building F No. 3 Yuancyu Street

115 03, Taipei

http://www.medigen.com.tw

address Medigen Biotechnology Corp.(3176)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MEDIGEN BIOTECHNOLOGY CORP.	-13.50%	165M
IQVIA HOLDINGS INC.	+1.12%	43.84B
MODERNA, INC.	+6.77%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.01%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	12.29B
MEDPACE HOLDINGS, INC.	+27.16%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.15B

Other Biotechnology & Medical Research